ReviewSurgery today2017
Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.
Review in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis.PloS one · 2019Pooled it
- The immunological paradox: immune checkpoint inhibitors in liver transplantation.International journal of clinical oncology · 2026Review
- Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.Annals of transplantation · 2026Article
- Evolving Transplant Oncology: Evolving Criteria for Better Decision-Making.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Transplant oncology - Current indications and strategies to advance the field.JHEP reports : innovation in hepatology · 2024Review
- Application of the IDEAL framework in hepatopancreatobiliary surgery: a review of the literature.Langenbeck's archives of surgery · 2023Review
- Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies.Medicina (Kaunas, Lithuania) · 2023Review
- Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology.Journal of Zhejiang University. Science. B · 2023Article
- Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.Current oncology (Toronto, Ont.) · 2022Article
- Artificial Intelligence: Present and Future Potential for Solid Organ Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2022Review
- The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma.Cancer science · 2021Article
- Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021Article
- Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine.Frontiers in surgery · 2021Review
- Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going.Langenbeck's archives of surgery · 2020Review
- Selection of Hepatocellular Carcinoma Patients for Liver Transplantation: Should the Threshold for Expected Oncological Survival Be Lowered?Transplantation direct · 2019Article
- Adjuvant treatment in biliary tract cancer.Translational cancer research · 2019Review
- Liver transplantation for irresectable colorectal liver metastases: still a contraindication?Hepatobiliary surgery and nutrition · 2018Article
- Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint.Hepatobiliary surgery and nutrition · 2018Article
- Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology.Gland surgery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The indications of liver transplantation for hepatobiliary malignancies have been carefully expanded in a stepwise fashion, despite the fundamental limitations in oncological, immunological, and technical aspects. A new era of "Transplant Oncology," the fusion of transplant surgery and surgical oncology, has begun, and we stand at the dawn of a paradigm shift in multidisciplinary cancer treatment. For hepatocellular carcinoma, new strategies have been undertaken to select recipients based on biological and dynamic markers instead of conventional morphological and static parameters, opening the doors for a more deliberate expansion of the Milan criteria and locoregional therapies before liver transplantation. Neoadjuvant chemoradiation therapy followed by liver transplantation for unresectable perihilar cholangiocarcinoma developed by the Mayo Clinic provided excellent outcomes in a US multicenter study; however, the surgical indications are not necessarily universal and await international validation. Similarly, an aggressive multidisciplinary approach has been applied for other tumors, including intrahepatic cholangiocarcinoma, hepatoblastoma, liver metastases from colorectal and neuroendocrine primary and gastrointestinal stromal tumors as well as rare tumors, such as hepatic undifferentiated embryonal sarcoma and infantile choriocarcinoma. In conclusion, liver transplantation is an important option for hepatobiliary malignancies; however, prospective studies are urgently needed to ensure the appropriate patient selection, organ allocation and living donation policies, and administration of antineoplastic immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.